Aigen Investment Management LP Invests $230,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Aigen Investment Management LP purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 8,042 shares of the specialty pharmaceutical company’s stock, valued at approximately $230,000.

A number of other large investors have also recently added to or reduced their stakes in the business. TD Private Client Wealth LLC raised its position in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the period. KBC Group NV increased its position in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the period. Virtus Fund Advisers LLC purchased a new stake in Collegium Pharmaceutical in the 3rd quarter valued at about $72,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 642 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have recently issued reports on COLL. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Friday, January 10th. Finally, Piper Sandler decreased their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders sold 93,567 shares of company stock worth $2,774,710. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Down 3.0 %

Shares of COLL opened at $28.91 on Monday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock has a market capitalization of $910.26 million, a PE ratio of 12.46 and a beta of 0.99. The company’s 50-day simple moving average is $30.78 and its 200-day simple moving average is $33.19. Collegium Pharmaceutical, Inc. has a 1 year low of $27.28 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.